ClinicalTrials.gg
CompletedNCT01628107AiME - 03Updated Jul 19, 2018Results posted

A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

A Phase 3 interventional study of Epoetin Hospira in Chronic Renal Failure Requiring Hemodialysis, sponsored by Pfizer. Completed at 110 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-07-19.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
406
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing Epoetin Alfa in Kidney Failure, Chronic — none open to participants now, none under way, none of them phase 3. Epoetin Alfa · Kidney Failure, Chronic.

Enrollment
5th of 13
406 · median 292
Started
2012
with 4 others
Phase 3
5 of 13
none open now
Registered
11th of 13
by date
Lead sponsor
4 of 13
Pfizer

Among the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic, this one is the 5th largest by enrollment, is one of 5 that started in 2012, is one of 5 in phase 3, and was the 11th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic is open now. The open studies under Kidney Failure, Chronic, anywhere →

Where they have run

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic as a file.
02

Study summary

The purpose of the study is to determine the long-term safety in treatment-emergent adverse events (TEAEs) of intravenous (IV) administration of Epoetin Hospira for maintenance of target hemoglobin (Hgb) levels in patients treated for anemia associated with chronic renal failure and on hemodialysis.

03

Conditions studied

  • Chronic Renal Failure Requiring Hemodialysis

Keywords

  • Chronic renal failure
  • hemodialysis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is able to provide written after the risks and benefits of the study have been explained prior to any study-related activities.
  2. Patient previously completed the core study Treatment Period up to and including Week 24 study assessments per protocol and is willing to continue open-label Epoetin Hospira for up to 48 weeks.
  3. If female, patient must be for at least 1 year prior to enrollment, surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or practicing at least 1 of the following methods of :

    • Hormonal contraceptives (oral, parenteral, or transdermal) for at least 3 months prior to enrollment
    • Intrauterine device
    • Double-barrier method (condoms, contraceptive sponge, diaphragm, or vaginal ring with spermicidal jellies or cream)

    If hormonal contraceptives are used, the specific contraceptive must have been used for at least 3 months prior to enrollment. If the patient is currently using a hormonal contraceptive, she should also use a barrier method during this study and for at least 30 days following the administration of the patient's last open-label dose.

  4. Adequate methods of contraception to prevent pregnancy are to be maintained throughout the course of the study in both male and female study subjects.

Exclusion criteria

Exclusion Criteria:

  1. Patient had a serious or severe adverse event in the core study that, in the opinion of the Investigator, was probably or definitely related to epoetin use and precluded safe use of epoetin.
  2. Any of the following that developed during the core study and prior to enrollment:

    • Myocardial infarction
    • Stroke (cerebrovascular accident)/cerebrovascular insult (minor stroke) or /intracerebral bleeding/cerebral infarction
    • Severe/unstable angina
    • Coronary angioplasty, bypass surgery, or peripheral artery bypass graft
    • Decompensated congestive heart failure ( [NYHA] class IV)
    • Pulmonary embolism
    • Deep vein thrombosis or other thromboembolic event
    • Received live or attenuated vaccination (except flu vaccination)
  3. A patient with any active, uncontrolled systemic, inflammatory, or malignant disease that developed during the core study and in the Investigator's opinion may be significant to exclude participation in the study, including but not limited to demyelinating diseases such as multiple sclerosis, microbial, viral, or fungal infection or mental disease.
  4. Any newly developed significant drug sensitivity or a significant allergic reaction to any drug, as well as known or idiosyncratic reaction to epoetin (or its , including albumin) or any other related drugs that in the judgment of the Investigator is exclusionary for study participation.
  5. A female patient who is pregnant, lactating, or planning a pregnancy during the study.
  6. History of drug abuse or alcohol abuse during the core study prior to enrollment as determined by the Investigator.
  7. Current participation or participation in a drug or other research study within 30 days prior to enrollment (except the core study or any observational studies with prior written approval from Hospira).
  8. May not be able to comply with the requirements of this clinical study, communicate effectively with study personnel, or is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
  9. Evidence of (HIV) or surface antigen (HBsAg).
  10. A patient who, in the Investigator's opinion, has any abnormal laboratory results that may impact patient safety.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
406 participants (actual)

Study arms

  • Experimental
    Epoetin Hospira

    Epoetin Hospira will be administered by IV bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.

    Biological: Epoetin Hospira

Interventions

  • BiologicalEpoetin Hospira

    Intravenous (IV) injection

    Also known as: ESA, Erythropoetin Stimulating Agent

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Up through 7 days after first dose of study drug (Week 1)

  2. Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 12

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Week 1 up to Week 12

  3. Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 13 to 24

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Week 13 up to Week 24

  4. Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 25 to 36

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Week 25 up to Week 36

  5. Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 37 to 48

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Week 37 up to Week 48

  6. Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 48

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Week 1 up to Week 48

Secondary outcomes

  1. Mean Weekly Dosage of Epoetin Hospira : Over Week 1 to 48

    Time frame: Week 1 up to Week 48

  2. Mean Weekly Dosage of Epoetin Hospira for Interval of 12 Weeks

    Time frame: Week 1 up to Week 12; Week 13 up to Week 24; Week 25 up to Week 36; Week 37 up to Week 48

  3. Mean Hemoglobin Levels: Over Week 1 to 48

    Time frame: Week 1 up to Week 48

  4. Mean Hemoglobin Levels for Interval of 12 Weeks

    Time frame: Week 1 up to Week 12; Week 13 up to Week 24; Week 25 up to Week 36; Week 37 up to Week 48

  5. Mean Hematocrit Levels: Over Week 1 to 48

    Hematocrit is defined as the percentage of red blood cells in the blood.

    Time frame: Week 1 up to Week 48

  6. Mean Hematocrit Levels for Interval of 12 Weeks

    Hematocrit is defined as the percentage of red blood cells in the blood.

    Time frame: Week 1 up to Week 12; Week 13 up to Week 24; Week 25 up to Week 36; Week 37 up to Week 48

  7. Percentage of Participants With Hemoglobin Level Outside the Target Range

    Percentage of participants with hemoglobin level outside the target range of 9.0 to 11.0 g/dL were reported.

    Time frame: Week 1 up to Week 48

  8. Percentage of Participants Who Received Blood Transfusions

    Time frame: Week 1 up to Week 48

Other outcomes

  1. Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)

    Time frame: Week 1 up to Week 48

  2. Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)

    Time frame: Week 1 up to Week 48

  3. Number of Participants With Clinically Significant Change From Baseline in Hemoglobin Levels

    Participants with clinically significant change from baseline in hemoglobin levels were upon investigator's discretion.

    Time frame: Baseline up to Week 48

  4. Number of Participants Who Received Concomitant Medication

    Time frame: Week 1 up to Week 48

  5. Number of Participants With Clinically Significant Change From Baseline in Laboratory Tests

    Laboratory tests included: Hematology (hematocrit, hemoglobin, red blood cells count, reticulocytes, white blood cells count, neutrophils, bands, lymphocytes, monocytes, basophils, eosinophils, platelets, mean corpuscular volume); Coagulation panel (prothrombin time, international normalized ratio, activated partial thromboplastin time); Chemistry (blood urine nitrogen, creatinine, total bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, sodium, potassium, magnesium, calcium, gamma-glutyl transpeptidase, phosphorus, uric acid, total protein, glucose, albumin, C-reactive protein); iron status (plasma ferritin, transferrin saturation). Participants with clinically significant change from baseline in laboratory tests were based on investigator's discretion.

    Time frame: Baseline up to Week 48

  6. Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiogram (ECG)

    ECG parameters included: PR interval, QRS complex, QT interval and QTC interval. Participants with clinically significant change from baseline in 12-lead ECGs were based on investigator's discretion.

    Time frame: Baseline up to Week 48

  7. Number of Participants With Clinically Significant Change From Baseline in Physical Examinations

    Physical examination included examination of the skin, eyes, ears, nose, throat, head, neck, thyroid, lungs, chest, abdomen, extremities, lymphatic, cardiovascular, musculoskeletal and neurological systems. Participants for any clinically significant changes in physical examination were based on the investigator's discretion.

    Time frame: Baseline up to Week 48

  8. Percentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies

    Percentage of participants with at least 1 positive anti-rhEPO antibody were reported. Radioimmunoprecipitation assay was used to determine the presence of anti-rhEPO antibodies.

    Time frame: Baseline, Week 48

07

Results

Posted Jul 19, 2018

Participant flow

Participants with chronic renal failure were receiving Epoetin maintenance therapy in study EPOE-10-01 (NCT01473407) prior to enrollment and treatment in the current study.

Participant flow — Overall Study
MilestoneEpoetin Hospira
Started414
Treated406
Completed295
Not completed119
Withdrew: Withdrawal by subject17
Withdrew: Lost to follow-up4
Withdrew: Adverse event33
Withdrew: Physician decision2
Withdrew: Not met inclusion/exclusion criteria1
Withdrew: Non-compliant with study procedures10
Withdrew: Not treated8
Withdrew: Sponsor decision11
Withdrew: Missed study drug more than 2 weeks7
Withdrew: Relocated8
Withdrew: Kidney transplant9
Withdrew: Use of standard of care9

Outcome measures

PrimaryPercentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Up through 7 days after first dose of study drug (Week 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1
Percentage of participantsEpoetin Hospira
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 113.0
PrimaryPercentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 12

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Week 1 up to Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 12
Percentage of participantsEpoetin Hospira
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 1259.4
PrimaryPercentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 13 to 24

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Week 13 up to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 13 to 24
Percentage of participantsEpoetin Hospira
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 13 to 2457.5
PrimaryPercentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 25 to 36

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Week 25 up to Week 36
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 25 to 36
Percentage of participantsEpoetin Hospira
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 25 to 3654.3
PrimaryPercentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 37 to 48

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Week 37 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 37 to 48
Percentage of participantsEpoetin Hospira
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 37 to 4851.7
PrimaryPercentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 48

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Week 1 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 48
Percentage of participantsEpoetin Hospira
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 4885.7
SecondaryMean Weekly Dosage of Epoetin Hospira : Over Week 1 to 48
Time frame:
Week 1 up to Week 48
Reported as:
Mean · Unit per kilogram per week (U/kg/week)
Mean Weekly Dosage of Epoetin Hospira : Over Week 1 to 48
Unit per kilogram per week (U/kg/week)Epoetin Hospira
Mean Weekly Dosage of Epoetin Hospira : Over Week 1 to 4895.30 ± 85.515
SecondaryMean Weekly Dosage of Epoetin Hospira for Interval of 12 Weeks
Time frame:
Week 1 up to Week 12; Week 13 up to Week 24; Week 25 up to Week 36; Week 37 up to Week 48
Reported as:
Mean · U/kg/week
Mean Weekly Dosage of Epoetin Hospira for Interval of 12 Weeks
U/kg/weekEpoetin Hospira
Week 1 to Week 1294.93 ± 89.219
Week 13 to Week 2494.84 ± 89.303
Week 25 to Week 3694.01 ± 86.0
Week 37 to Week 4899.55 ± 95.510
SecondaryMean Hemoglobin Levels: Over Week 1 to 48
Time frame:
Week 1 up to Week 48
Reported as:
Mean · g/dL
Mean Hemoglobin Levels: Over Week 1 to 48
g/dLEpoetin Hospira
Mean Hemoglobin Levels: Over Week 1 to 4810.21 ± 0.629
SecondaryMean Hemoglobin Levels for Interval of 12 Weeks
Time frame:
Week 1 up to Week 12; Week 13 up to Week 24; Week 25 up to Week 36; Week 37 up to Week 48
Reported as:
Mean · g/dL
Mean Hemoglobin Levels for Interval of 12 Weeks
g/dLEpoetin Hospira
Week 1 to Week 1210.26 ± 0.789
Week 13 to Week 2410.25 ± 0.762
Week 25 to Week 3610.18 ± 0.865
Week 37 to Week 4810.21 ± 0.818
SecondaryMean Hematocrit Levels: Over Week 1 to 48

Hematocrit is defined as the percentage of red blood cells in the blood.

Time frame:
Week 1 up to Week 48
Reported as:
Mean · Percentage of red blood cells
Mean Hematocrit Levels: Over Week 1 to 48
Percentage of red blood cellsEpoetin Hospira
Mean Hematocrit Levels: Over Week 1 to 4832.17 ± 2.164
SecondaryMean Hematocrit Levels for Interval of 12 Weeks

Hematocrit is defined as the percentage of red blood cells in the blood.

Time frame:
Week 1 up to Week 12; Week 13 up to Week 24; Week 25 up to Week 36; Week 37 up to Week 48
Reported as:
Mean · Percentage of red blood cells
Mean Hematocrit Levels for Interval of 12 Weeks
Percentage of red blood cellsEpoetin Hospira
Week 1 to Week 1232.26 ± 2.695
Week 13 to Week 2432.21 ± 2.569
Week 25 to Week 3632.03 ± 2.978
Week 37 to Week 4832.17 ± 2.738
SecondaryPercentage of Participants With Hemoglobin Level Outside the Target Range

Percentage of participants with hemoglobin level outside the target range of 9.0 to 11.0 g/dL were reported.

Time frame:
Week 1 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Hemoglobin Level Outside the Target Range
Percentage of participantsEpoetin Hospira
Percentage of Participants With Hemoglobin Level Outside the Target Range90.1
SecondaryPercentage of Participants Who Received Blood Transfusions
Time frame:
Week 1 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Received Blood Transfusions
Percentage of participantsEpoetin Hospira
Percentage of Participants Who Received Blood Transfusions9.7
Other pre-specifiedPercentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)
Time frame:
Week 1 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)
Percentage of participantsEpoetin Hospira
Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)13.9
Other pre-specifiedPercentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)
Time frame:
Week 1 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)
Percentage of participantsEpoetin Hospira
Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)20.9
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Hemoglobin Levels

Participants with clinically significant change from baseline in hemoglobin levels were upon investigator's discretion.

Time frame:
Baseline up to Week 48
Reported as:
Number · Participants
Number of Participants With Clinically Significant Change From Baseline in Hemoglobin Levels
ParticipantsEpoetin Hospira
Number of Participants With Clinically Significant Change From Baseline in Hemoglobin Levels0
Other pre-specifiedNumber of Participants Who Received Concomitant Medication
Time frame:
Week 1 up to Week 48
Reported as:
Number · Participants
Number of Participants Who Received Concomitant Medication
ParticipantsEpoetin Hospira
Number of Participants Who Received Concomitant Medication406
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Laboratory Tests

Laboratory tests included: Hematology (hematocrit, hemoglobin, red blood cells count, reticulocytes, white blood cells count, neutrophils, bands, lymphocytes, monocytes, basophils, eosinophils, platelets, mean corpuscular volume); Coagulation panel (prothrombin time, international normalized ratio, activated partial thromboplastin time); Chemistry (blood urine nitrogen, creatinine, total bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, sodium, potassium, magnesium, calcium, gamma-glutyl transpeptidase, phosphorus, uric acid, total protein, glucose, albumin, C-reactive protein); iron status (plasma ferritin, transferrin saturation). Participants with clinically significant change from baseline in laboratory tests were based on investigator's discretion.

Time frame:
Baseline up to Week 48
Reported as:
Number · Participants
Number of Participants With Clinically Significant Change From Baseline in Laboratory Tests
ParticipantsEpoetin Hospira
Number of Participants With Clinically Significant Change From Baseline in Laboratory Tests0
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiogram (ECG)

ECG parameters included: PR interval, QRS complex, QT interval and QTC interval. Participants with clinically significant change from baseline in 12-lead ECGs were based on investigator's discretion.

Time frame:
Baseline up to Week 48
Reported as:
Number · Participants
Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiogram (ECG)
ParticipantsEpoetin Hospira
Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiogram (ECG)2
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Physical Examinations

Physical examination included examination of the skin, eyes, ears, nose, throat, head, neck, thyroid, lungs, chest, abdomen, extremities, lymphatic, cardiovascular, musculoskeletal and neurological systems. Participants for any clinically significant changes in physical examination were based on the investigator's discretion.

Time frame:
Baseline up to Week 48
Reported as:
Number · Participants
Number of Participants With Clinically Significant Change From Baseline in Physical Examinations
ParticipantsEpoetin Hospira
Number of Participants With Clinically Significant Change From Baseline in Physical Examinations0
Other pre-specifiedPercentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies

Percentage of participants with at least 1 positive anti-rhEPO antibody were reported. Radioimmunoprecipitation assay was used to determine the presence of anti-rhEPO antibodies.

Time frame:
Baseline, Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies
Percentage of participantsEpoetin Hospira
Baseline0
Week 480.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epoetin Hospira—168/406 (41.4%)277/406 (68.2%)
Most frequent serious events
Showing 10 of 203
Most frequent serious events
EventEpoetin Hospira
SepsisInfections and infestations18/406
PneumoniaInfections and infestations16/406
Acute myocardial infarctionCardiac disorders13/406
HyperkalaemiaMetabolism and nutrition disorders13/406
Cardiac failure congestiveCardiac disorders10/406
Angina pectorisCardiac disorders7/406
Cardio-respiratory arrestCardiac disorders7/406
Cardiac arrestCardiac disorders6/406
HypoglycaemiaMetabolism and nutrition disorders6/406
HypertensionVascular disorders6/406
Most frequent other events
Showing 10 of 19
Most frequent other events
EventEpoetin Hospira
Muscle spasmsMusculoskeletal and connective tissue disorders81/406
NauseaGastrointestinal disorders58/406
HeadacheNervous system disorders51/406
DiarrhoeaGastrointestinal disorders49/406
DizzinessNervous system disorders47/406
DyspnoeaRespiratory, thoracic and mediastinal disorders42/406
HypotensionVascular disorders41/406
VomitingGastrointestinal disorders39/406
CoughRespiratory, thoracic and mediastinal disorders36/406
Arteriovenous fistula site complicationInjury, poisoning and procedural complications35/406

Baseline characteristics

Safety analysis set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Epoetin Hospira
Mean57.45 ± 12.062
Sex: Female, Male
Sex: Female, Male(Participants)Epoetin Hospira
Female169
Male237
08

Study locations

110 sites
  • North America Research Institute
    Azusa, California 91702, United States
  • Bellflower Dialysis Center
    Bellflower, California 90706, United States
  • National Institute of Clinical Research
    Commerce, California 90040, United States
  • DaVita Premier Dialysis Center
    Cudahy, California 90201, United States
  • Davita - South Valley Dialysis
    Encino, California 91316, United States
  • Ong, Rubin, Shahmir A Medical Corp DBA: Solano Kidney Care
    Fairfield, California 94533, United States
  • Fairfield Dialysis Center
    Fairfield, California 94534, United States
  • Renal Consultants Medical Group
    Granada Hills, California 91344, United States
  • Advanced Medical Research (Administrative)
    Lakewood, California 90712, United States
  • Long Beach Clinical Trials
    Long Beach, California 90806, United States
  • Westcoast Dialysis
    Long Beach, California 90806, United States
  • DaVita Bixby Knolls Dialysis
    Long Beach, California 90807, United States
  • United Dialysis Center
    Long Beach, California 90807, United States
  • Long Beach Dialysis
    Long Beach, California 90813, United States
  • Imperial Care Dialysis Center
    Lynwood, California 90262, United States
  • Kidney Research Center
    Lynwood, California 90262, United States
  • Modesto Kidney Center
    Modesto, California 95350, United States
  • Novo Research d/b/a Foundation Research
    Modesto, California 95350, United States
  • Parkway Kindey Center
    Modesto, California 95350, United States
  • Oakdale Kidney Center
    Oakdale, California 95361, United States
  • National Institute of Clinical Research
    Ontario, California 91762, United States
  • Ontario Dialysis Center
    Ontario, California 91762, United States
  • Paramount Dialysis Center
    Paramount, California 90723, United States
  • Sierra View Dialysis Center
    Porterville, California 93257, United States
  • Sierra View District Hospital Dialysis Center
    Porterville, California 93257, United States
  • Sierra View District Hospital
    Porterville, California 93257, United States
  • Sierra View Nephrology, Inc.
    Porterville, California CA, United States
  • Nephrology Educational Services and Research, Inc
    Tarzana, California 91356, United States
  • Santa Clarita Kidney Center
    Valencia, California 91355, United States
  • American Institute of Research
    Whittier, California 90603, United States
  • Santa Fe Springs Dialysis
    Whittier, California 90606, United States
  • Nephrology and Hypertension Associates,PC
    Middlebury, Connecticut 06762, United States
  • Waterbury Dialysis Center
    Waterbury, Connecticut 06705, United States
  • Greater Waterbury Dialysis
    Waterbury, Connecticut 06708, United States
  • Innovative Medical Research of South Florida, Inc,
    Aventura, Florida 33180, United States
  • West Boca Dialysis Center
    Boca Raton, Florida 33434, United States
  • Florida Kidney Center
    Lauderhill, Florida 33319, United States
  • South Florida Research Institute
    Laureda Lake, Florida 33313, United States
  • Coconut Creek Dialysis JV
    Margate, Florida 33063, United States
  • American Renal Associates Naples Dialysis Center
    Naples, Florida 34119, United States
  • Innovative Medical Research of South Florida, Inc.
    North Miami Beach, Florida 33169, United States
  • Physicians Dialysis of North Beach
    North Miami Beach, Florida 33169, United States
  • Discovery Medical Research Group, Inc.,
    Ocala, Florida 34471, United States
  • Discovery Medical Research Group, Inc.
    Ocala, Florida 34471, United States
  • Ocala Regional Kidney Center, East
    Ocala, Florida 34471, United States
  • Silver Springs Shores Dialysis Center
    Ocala, Florida 34472, United States
  • Ft. Lauderdale Kidney Center
    Plantation, Florida 33312, United States
  • Plantation Kidney Center
    Plantation, Florida 33324, United States
  • Tamarac Kidney Center
    Tamarac, Florida 33321, United States
  • Dialysis of Dublin
    Dublin, Georgia 31021, United States
  • Renal Physicians of Georgia, PC
    Dublin, Georgia 31021, United States
  • Liberty Dialysis/Boise Kidney & Hypertension Institute
    Caldwell, Idaho 83605, United States
  • Liberty Dialysis/Boise Kidney & Hypertension Institute
    Meridian, Idaho 83642, United States
  • Pacific Renal Research Institute/Boise Kidney & Hypertension Institute
    Meridian, Idaho 83642, United States
  • Liberty Dialysis/Boise Kidney & Hypertension Institute
    Nampa, Idaho 83686, United States
  • Neomedica South
    Chicago, Illinois 60617, United States
  • FMC Ross Englewood Dialysis
    Chicago, Illinois 60621, United States
  • Neomedica Evergreen Park
    Evergreen Park, Illinois 60805, United States
  • Research by Design, LLC
    Evergreen Park, Illinois 60805, United States
  • North Suburban Nephrology, LLC
    Gurnee, Illinois 60031, United States
  • Neomedica Round Lake
    Round Lake, Illinois 60073, United States
  • Clinton Township Dialysis
    Clinton Township, Michigan 48038, United States
  • Grosse Pointe Dialysis
    Detroit, Michigan 48224, United States
  • Renaissance Renal Research Institute, LLC
    Detroit, Michigan 48236, United States
  • Biloxi Dialysis
    Biloxi, Mississippi 39530, United States
  • FMC/South Mississippi Kidney Center of Gulfport
    Gulfport, Mississippi 39501, United States
  • South Mississippi Medical Research, PLLC
    Gulfport, Mississippi 39501, United States
  • Barnes-Jewish Dialysis Center
    Saint Louis, Missouri 63108, United States
  • Chromalloy American Kidney Center Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Lower Manhattan Dialysis Center II
    New York, New York 10003, United States
  • Mountain Kidney and Hypertension Associates, P A
    Asheville, North Carolina 28801, United States
  • Asheville Kidney Center
    Asheville, North Carolina 28805, United States
  • ECU Nephrology and Hypertension
    Greenville, North Carolina 27834-2847, United States
  • East Carolina University
    Greenville, North Carolina 27834, United States
  • Cincinnati VA Medical Center
    Cincinnati, Ohio 45220, United States
  • Fresenius Greater Columbus Regional Dialysis Center
    Columbus, Ohio 43215, United States
  • HNC Dialysis, Ltd.
    Columbus, Ohio 43215, United States
  • Delaware Valley Nephrology and Hypertension Associates, PC
    Philadelphia, Pennsylvania 19118, United States
  • Fresenius Medical Care- Mt. Airy Kidney Center
    Philadelphia, Pennsylvania 19118, United States
  • Fresenius Medical Care - Olney Dialysis Center
    Philadelphia, Pennsylvania 19138, United States
  • Anderson Dialysis Clinic
    Anderson, South Carolina 29621, United States
  • AnMed Health
    Anderson, South Carolina 29621, United States
  • Nephrology and Internal Medicine of Anderson
    Anderson, South Carolina 29621, United States
  • Columbia Nephrology Associates, P. A.
    Columbia, South Carolina 29203, United States
  • Columbia Nephrology Associates, PA
    Columbia, South Carolina 29203, United States
  • Fresenius Medical Care Columbia JV
    Columbia, South Carolina 29203, United States
  • Fresenius Medical Care Meadowlake JV
    Columbia, South Carolina 29203, United States
  • Fresenius Medical Care South Columbia JV
    Columbia, South Carolina 29203, United States
  • Fresenius Medical Care SE Columbia JV
    Columbia, South Carolina 29209, United States
  • Sumter Dialysis Clinic
    Sumter, South Carolina 29150, United States
  • Gamma Medical Research Inc.
    Edinburg, Texas 78539, United States
  • Med Center Dialysis
    Houston, Texas 77004, United States
  • Fresenius Medical Care Kidney Center
    Houston, Texas 77030, United States
  • Meyerland Dialysis
    Houston, Texas 77035, United States
  • Millennium Clinical Research, Inc.
    Houston, Texas 77054, United States
  • Southwest Houston Dialysis
    Houston, Texas 77071, United States
  • DaVita North Park
    Houston, Texas 77073, United States
  • North Shepherd Dialysis Center
    Houston, Texas 77091, United States
  • Southwest Houston Research, Ltd.
    Houston, Texas 77099, United States
  • Dialysis Center of Lubbock
    Lubbock, Texas 79430, United States

Showing the first 100 of 110 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Wish JB, Rocha MG, Martin NE, Reyes CRD, Fishbane S, Smith MT, Nassar G. Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies. Kidney Med. 2019 Aug 28;1(5):271-280. doi: 10.1016/j.xkme.2019.06.009. eCollection 2019 Sep-Oct. PubMed 32734207 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2012 to primary completion in Jan 2015, 29 months.

Results were first posted in Jul 2018, 3 years 6 months after primary completion. A results delay was requested in Dec 2015.

Of 42 industry-sponsored phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 40. This study's 29 months is close to that.

Counting every sponsor, half of 66 studies reached it within 32 months; a quarter within 21 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2012
First posted
Jun 26, 2012
StartActual
Jul 16, 2012
Primary completionActual
Jan 2, 2015
CompletionActual
Jan 2, 2015
Results delay requested
Dec 22, 2015
Results first posted
Jul 19, 2018
Last update
Jul 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01628107
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 26, 2012
Start date
Jul 16, 2012
Primary completion
Jan 2, 2015
Completion
Jan 2, 2015
Results posted
Jul 19, 2018
Last update
Jul 19, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion